Since 2000, the annual Work Plan of the Office of the Inspector General (OIG) listed clinical research and clinical trials as a compliance target. As a result, sponsors, investigators, and institutions have increased their vigilance over the operation of clinical research activities. Have those efforts been in the right direction? Have they been enough?
This session will focus on learning the perspective, understanding the actions, and preparing to respond to the OIG’s position and priorities.